Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin s...

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Associated Therapies: -

Clinical Trials

Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants

Phase 2

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: TNP-2198
Drug: Rabeprazole Sodium
Drug: Amoxicillin

First Posted Date: 2023-10-11

Last Posted Date: 2023-12-12

Lead Sponsor: TenNor Therapeutics (Suzhou) Limited

Target Recruit Count: 80

Registration Number: NCT06076694

Locations: 🇨🇳
The First Hospital of Jilin University, Chang chun, Jilin, China

Modified Dosage for Severe Acute Malnutrition

Not Applicable

Recruiting

Conditions: Severe Acute Malnutrition

Interventions: Dietary Supplement: ready-to-use therapeutic food (RUTF)
Drug: Amoxicillin

First Posted Date: 2023-09-29

Last Posted Date: 2024-07-16

Lead Sponsor: Action Against Hunger USA

Target Recruit Count: 2400

Registration Number: NCT06061484

Locations: 🇪🇹
Gode, Gode, Somali Region, Ethiopia
🇪🇹
Teltele, Teltele, Oromia, Ethiopia
🇪🇹
Sekota, Sekota, Amhara, Ethiopia

Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition

Phase 4

Not yet recruiting

Conditions: Severe Acute Malnutrition
Malnutrition, Child

Interventions: Drug: Amoxicillin
Other: Placebo
Drug: Azithromycin

First Posted Date: 2023-08-25

Last Posted Date: 2024-10-16

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 3000

Registration Number: NCT06010719

Locations: 🇧🇫
Centre de recherche en Santé de nouna, Nouna, Kossi, Burkina Faso

A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile

Not Applicable

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Lansoprazole
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Metronidazole

First Posted Date: 2023-07-03

Last Posted Date: 2024-12-20

Lead Sponsor: Miguel O'Ryan Gallardo

Target Recruit Count: 500

Registration Number: NCT05926804

Locations: 🇨🇱
Universidad de Chile, Santiago, Chile
🇨🇱
Universidad de Aysén, Coyhaique, Chile
🇨🇱
Universidad de la Frontera, Temuco, Chile

High-dose Dual Therapy With Different Administration Frequencies

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: vonoprazan
Drug: Amoxicillin

First Posted Date: 2023-06-13

Last Posted Date: 2023-12-21

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 327

Registration Number: NCT05901051

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Rescue Therapy for Helicobacter Pylori Infection

Phase 4

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Vonoprazan
Drug: Bismuth Potassium Citrate
Drug: Amoxicillin
Drug: Tetracycline
Drug: Rifabutin
Drug: Metronidazole

First Posted Date: 2023-05-25

Last Posted Date: 2024-10-22

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 357

Registration Number: NCT05874544

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳
Shanghai Songjiang District Central Hospital, Shanghai, Shanghai, China
🇨🇳
The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, Zhejiang, China

Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）

Not Applicable

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Tegoprazan
Drug: Amoxicillin
Drug: Esomeprazole

First Posted Date: 2023-05-23

Last Posted Date: 2023-07-11

Lead Sponsor: Yanqing Li

Target Recruit Count: 368

Registration Number: NCT05870683

Locations: 🇨🇳
Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China

Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children

Phase 2

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Esomeprazole
Drug: Lansoprazole
Drug: Amoxicillin
Drug: Clarithromycin

First Posted Date: 2023-05-17

Last Posted Date: 2023-05-17

Lead Sponsor: Finni Kollins

Target Recruit Count: 51

Registration Number: NCT05861687

Locations: 🇮🇩
Universitas Sumatera Utara General Hospital, Medan, North Sumatera, Indonesia
🇮🇩
Haji Adam Malik General Hospital, Medan, North Sumatera, Indonesia